Novo rapped by FDA for not reporting drug adverse effects Novo Nordisk has been sent a warning letter from the FDA for violations of postmarketing adverse drug experience (PADE) regulations.

#NovoNordisk has been sent a #warningletter from the #FDA for a series of violations of postmarketing #adversedrugexperience (PADE) regulations, including failure to report #sideeffects among patients using its #GLP1 drugs for diabetes and weight loss.

pharmaphorum.com/news/novo-ra...